Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis

World Journal of Gastroenterology

Volumn 22, Issue 2, 2016, Pages 519-533

  Brandi, Giovanni ^a   De Lorenzo, Stefania ^a   Nannini, Margherita ^a   Curti, Stefania ^b   Ottone, Marta ^b   Dall'Olio, Filippo Gustavo ^a   Barbera, Maria Aurelia ^a   Pantaleo, Maria Abbondanza ^a   Biasco, Guido ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Adjuvant chemotherapy; Adjuvant hepatic artery infusion; Colorectal cancer; Liver metastases; Metastasectomy

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLOXURIDINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; REGORAFENIB; ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CRYOSURGERY; CRYOTHERAPY; DRUG EFFICACY; DRUG SAFETY; HUMAN; LIVER METASTASIS; LIVER RESECTION; LUNG METASTASIS; META ANALYSIS; METASTASIS; METASTASIS RESECTION; METASTATIC COLORECTAL CANCER; MICROWAVE THERAPY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGIONAL PERFUSION; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT RESPONSE; WEDGE RESECTION; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; COLORECTAL TUMOR; HEPATIC ARTERY; INTRAARTERIAL DRUG ADMINISTRATION; LIVER NEOPLASMS; MORTALITY; PATHOLOGY; PROCEDURES; RISK FACTOR; SECONDARY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; HEPATECTOMY; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; METASTASECTOMY; RISK FACTORS; TREATMENT OUTCOME;

EID: 84954448535     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i2.519     Document Type: Review

References (117)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29 [PMID: 25559415 DOI: 10.3322/caac.21254]
2. Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O'Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R, de Gramont A. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20, 898 patients on 18 randomized trials. J Clin Oncol 2009; 27: 872-877 [PMID: 19124803 DOI: 10.1200/JCO.2008.19.5362]
3. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 Suppl 3: iii1-iii9 [PMID: 25190710 DOI: 10.1093/annonc/mdu260]
4. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D'Angelica M. Actual 10-year survival after resection of colorectal liver metastases defnes cure. J Clin Oncol 2007; 25: 4575-4580 [PMID: 17925551]
5. National Comprehensive Cancer Network. NCCN clinical practice in oncology: colon cancer. NCCN.org 2015, version 2. Available from: URL: http://guide.medlive.cn/guideline/7015
6. Biasco G, Derenzini E, Grazi G, Ercolani G, Ravaioli M, Pantaleo MA, Brandi G. Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. Cancer Treat Rev 2006; 32: 214-228 [PMID: 16546323]
7. Penna C, Nordlinger B. Colorectal metastasis (liver and lung). Surg Clin North Am 2002; 82: 1075-1090, x-xi [PMID: 12507210]
8. Yates LR, Campbell PJ. Evolution of the cancer genome. Nat Rev Genet 2012; 13: 795-806 [PMID: 23044827 DOI: 10.1038/nrg3317]
9. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature 2013; 501: 355-364 [PMID: 24048068 DOI: 10.1038/nature12627]
10. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013; 501: 338-345 [PMID: 24048066 DOI: 10.1038/nature12625]
11. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fuorouracil with or without oxaliplatin as frst-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947 [PMID: 10944126]
12. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047 [PMID: 10744089]
13. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fuorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214 [PMID: 15051767]
14. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used frst line. J Clin Oncol 2005; 23: 9441-9442 [PMID: 16361649]
15. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G. Phase III trial of infusional fuorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fuorouracil, leucovorin, and irinotecan (FOLFIRI) as frst-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676 [PMID: 17470860]
16. Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL. Oral capecitabine vs intravenous 5-fuorouracil and leucovorin: integrated effcacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004; 90: 1190-1197 [PMID: 15026800]
17. Díaz-Rubio E, Tabernero J, Gómez-España A, Massutí B, Sastre J, Chaves M, Abad A, Carrato A, Queralt B, Reina JJ, Maurel J, González-Flores E, Aparicio J, Rivera F, Losa F, Aranda E. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: fnal report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007; 25: 4224-4230 [PMID: 17548839]
18. Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as frst-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012 [PMID: 18421053 DOI: 10.1200/JCO.2007.14.9898]
19. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Souf-Mahjoubi R, Wang B, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-4786 [PMID: 17947725]
20. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasinska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034 [PMID: 24024839 DOI: 10.1056/NEJMoa1305275]
21. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065-1075 [PMID: 25088940 DOI: 10.1016/S1470-2045(14)70330-4]
22. Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY. PEAK: a randomized, multicenter phase II study of panitumumab plus modifed fuorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014; 32: 2240-2247 [PMID: 24687833 DOI: 10.1200/JCO.2013.53.2473]
23. Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guan ZZ, Mitchell L, Waterkamp D, Tabernero J. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 2013; 18: 1004-1012 [PMID: 23881988 DOI: 10.1634/theoncologist.2013-0107]
24. Cremolini C, Loupakis F, Falcone A. FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2015; 372: 291-292 [PMID: 25587960 DOI: 10.1056/NEJMc1413996]
25. Tol J, Koopman M, Rodenburg CJ, Cats A, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, Mol L, Antonini NF, Punt CJ. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 2008; 19: 734-738 [PMID: 18272912 DOI: 10.1093/annonc/mdm607]
26. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27: 672-680 [PMID: 19114685 DOI: 10.1200/JCO.2008.19.8135]
27. Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A, Arnold D; ESMO Guidelines Working Group. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6: vi64-vi72 [PMID: 24078664 DOI: 10.1093/annonc/mdt354]
28. Adjuvant chemotherapy with oxaliplatin, in combination with fluorouracil plus leucovorin prolongs disease-free survival, but causes more adverse events in people with stage II or III colon cancer Abstracted from: Andre T, Boni C, Mounedji-Boudiaf L, et al. Multicenter international study of oxaliplatin/5-fuorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fuorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-51.
29. Cancer Treat Rev 2004; 30: 711-713 [PMID: 15541581]
30. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116 [PMID: 19451431 DOI: 10.1200/JCO.2008.20.6771]
31. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25: 2198-2204 [PMID: 17470851]
32. Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll HJ. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011; 29: 1465-1471 [PMID: 21383294 DOI: 10.1200/JCO.2010.33.6297]
33. Twelves C, Wong A, Nowacki MP, Abt M, Burris H, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704 [PMID: 15987918]
34. Shimada Y, Hamaguchi T, Mizusawa J, Saito N, Kanemitsu Y, Takiguchi N, Ohue M, Kato T, Takii Y, Sato T, Tomita N, Yamaguchi S, Akaike M, Mishima H, Kubo Y, Nakamura K, Fukuda H, Moriya Y. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: fnal results of JCOG0205. Eur J Cancer 2014; 50: 2231-2240 [PMID: 24958736 DOI: 10.1016/j.ejca.2014.05.025]
35. Yoshida M, Ishiguro M, Ikejiri K, Mochizuki I, Nakamoto Y, Kinugasa Y, Takagane A, Endo T, Shinozaki H, Takii Y, Mochizuki H, Kotake K, Kameoka S, Takahashi K, Watanabe T, Watanabe M, Boku N, Tomita N, Nakatani E, Sugihara K. S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial). Ann Oncol 2014; 25: 1743-1749 [PMID: 24942277 DOI: 10.1093/annonc/mdu232]
36. Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields AL, Mayer RJ. Irinotecan fluorouracil plus leucovorin is not superior to fuorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007; 25: 3456-3461 [PMID: 17687149]
37. Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, Topham C, Tabernero J, André T, Sobrero AF, Mini E, Greil R, Di Costanzo F, Collette L, Cisar L, Zhang X, Khayat D, Bokemeyer C, Roth AD, Cunningham D. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009; 27: 3117-3125 [PMID: 19451425 DOI: 10.1200/JCO.2008.21.6663]
38. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, Atkins JN, Seay TE, Fehrenbacher L, Goldberg RM, O'Reilly S, Chu L, Azar CA, Lopa S, Wolmark N. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011; 29: 11-16 [PMID: 20940184 DOI: 10.1200/JCO.2010.30.0855]
39. de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F, Im SA, Bodoky G, Salazar R, Maindrault-Goebel F, Shacham-Shmueli E, Bajetta E, Makrutzki M, Shang A, André T, Hoff PM. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012; 13: 1225-1233 [PMID: 23168362 DOI: 10.1016/S1470-2045(12)70509-0]
40. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417 [PMID: 19339720 DOI: 10.1056/NEJMoa0805019]
41. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the frst-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671 [PMID: 19114683 DOI: 10.1200/JCO.2008.20.8397]
42. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH, Pockaj BA, Grothey A, Goldberg RM. Effect of oxaliplatin, fuorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 2012; 307: 1383-1393 [PMID: 22474202 DOI: 10.1001/jama.2012.385]
43. Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, van Laethem J, Thaler J, Bridgewater JA, Van Cutsem E, Rougier P, Collette L, Praet M, Schneider M,. Bouchè O, Lapage C, Girault C, Emile J, Laurent-Puig P, Bedenne L. Adjuvant FOLFOX-4 with or without cetuximab (CTX) in patients (PTS) with resected stage III colon cancer: DFS and OS results and subgroup analyses of the PETACC-8 Intergroup phase III trial. Ann Oncol 2012; 23 (suppl 9): abstract # LBA4
44. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, Marrero AM, Prasad M, Blumgart LH, Brennan MF. Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938-946 [PMID: 9060531]
45. D'Angelica M, Brennan MF, Fortner JG, Cohen AM, Blumgart LH, Fong Y. Ninety-six five-year survivors after liver resection for metastatic colorectal cancer. J Am Coll Surg 1997; 185: 554-559 [PMID: 9404879]
46. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990; 77: 1241-1246 [PMID: 2253003]
47. Steele G, Bleday R, Mayer RJ, Lindblad A, Petrelli N, Weaver D. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol 1991; 9: 1105-1112 [PMID: 2045852]
48. Choti MA, Sitzmann J V, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235: 759-766 [PMID: 12035031]
49. Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008; 247: 125-135 [PMID: 18156932]
50. Adam R, Bismuth H, Castaing D, Waechter F, Navarro F, Abascal A, Majno P, Engerran L. Repeat hepatectomy for colorectal liver metastases. Ann Surg 1997; 225: 51-60; discussion 60-62 [PMID: 8998120]
51. Petrowsky H, Gonen M, Jarnagin W, Lorenz M, DeMatteo R, Heinrich S, Encke A, Blumgart L, Fong Y. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 2002; 235: 863-871 [PMID: 12035044]
52. Adam R, Pascal G, Azoulay D, Tanaka K, Castaing D, Bismuth H. Liver resection for colorectal metastases: the third hepatectomy. Ann Surg 2003; 238: 871-873; discussion 883-884 [PMID: 14631224]
53. Morise Z, Sugioka A, Fujita J, Hoshimoto S, Kato T, Hasumi A, Suda T, Negi H, Hattori Y, Sato H, Maeda K. Does repeated surgery improve the prognosis of colorectal liver metastases? J Gastrointest Surg 2006; 10: 6-11 [PMID: 16368485]
54. Brandi G, Corbelli J, de Rosa F, Di Girolamo S, Longobardi C, Agostini V, Garajová I, La Rovere S, Ercolani G, Grazi GL, Pinna AD, Biasco G. Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases. Langenbecks Arch Surg 2012; 397: 1069-1077 [PMID: 22711237 DOI: 10.1007/s00423-012-0974-0]
55. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 1996; 77: 1254-1262 [PMID: 8608500]
56. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318; discussion 318-321 [PMID: 10493478]
57. Iwatsuki S, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham AC, Geller DA, Gayowski TJ, Fung JJ, Starzl TE. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 1999; 189: 291-299 [PMID: 10472930]
58. Nagashima I, Takada T, Matsuda K, Adachi M, Nagawa H, Muto T, Okinaga K. A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection. J Hepatobiliary Pancreat Surg 2004; 11: 79-83 [PMID: 15127268]
59. Konopke R, Kersting S, Distler M, Dietrich J, Gastmeier J, Heller A, Kulisch E, Saeger HD. Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int 2009; 29: 89-102 [PMID: 18673436 DOI: 10.1111/j.1478-3231.2008.01845.x]
60. Schindl M, Wigmore SJ, Currie EJ, Laengle F, Garden OJ. Prognostic scoring in colorectal cancer liver metastases: development and validation. Arch Surg 2005; 140: 183-189 [PMID: 15724001]
61. Gomez D, Cameron IC. Prognostic scores for colorectal liver metastasis: clinically important or an academic exercise? HPB (Oxford) 2010; 12: 227-238 [PMID: 20590892 DOI: 10.1111/j.1477-2574.2010.00158.x]
62. Ayez N, Lalmahomed ZS, van der Pool AE, Vergouwe Y, van Montfort K, de Jonge J, Eggermont AM, Ijzermans JN, Verhoef C. Is the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy? Ann Surg Oncol 2011; 18: 2757-2763 [PMID: 21638093 DOI: 10.1245/s10434-011-1819-8]
63. Schreckenbach T, Malkomes P, Bechstein WO, Woeste G, Schnitzbauer AA, Ulrich F. The clinical relevance of the Fong and the Nordlinger scores in the era of effective neoadjuvant chemotherapy for colorectal liver metastasis. Surg Today 2015; 45: 1527-1534 [PMID: 25563588]
64. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, Capussotti L, Vauthey JN. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005; 241: 715-722, discussion 722-724 [PMID: 15849507]
65. Truant S, Séquier C, Leteurtre E, Boleslawski E, Elamrani M, Huet G, Duhamel A, Hebbar M, Pruvot FR. Tumour biology of colorectal liver metastasis is a more important factor in survival than surgical margin clearance in the era of modern chemotherapy regimens. HPB (Oxford) 2015; 17: 176-184 [PMID: 25041611 DOI: 10.1111/hpb.12316]
66. Angelsen JH, Horn A, Eide GE, Viste A. Surgery for colorectal liver metastases: the impact of resection margins on recurrence and overall survival. World J Surg Oncol 2014; 12: 127 [PMID: 24767422 DOI: 10.1186/1477-7819-12-127]
67. Andreou A, Aloia TA, Brouquet A, Dickson P V, Zimmitti G, Maru DM, Kopetz S, Loyer EM, Curley SA, Abdalla EK, Vauthey JN. Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg 2013; 257: 1079-1088 [PMID: 23426338 DOI: 10.1097/SLA.0b013e318283a4d1]
68. Sadot E, Groot Koerkamp B, Leal JN, Shia J, Gonen M, Allen PJ, DeMatteo RP, Kingham TP, Kemeny N, Blumgart LH, Jarnagin WR, D'Angelica MI. Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate? Ann Surg 2015; 262: 476-485; discussion 483-485 [PMID: 26258316 DOI: 10.1097/SLA.0000000000001427]
69. Zorzi D, Mullen JT, Abdalla EK, Pawlik TM, Andres A, Muratore A, Curley SA, Mentha G, Capussotti L, Vauthey JN. Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. J Gastrointest Surg 2006; 10: 86-94 [PMID: 16368496]
70. Guzzetti E, Pulitanò C, Catena M, Arru M, Ratti F, Finazzi R, Aldrighetti L, Ferla G. Impact of type of liver resection on the outcome of colorectal liver metastases: a case-matched analysis. J Surg Oncol 2008; 97: 503-507 [PMID: 18425789 DOI: 10.1002/jso.20979]
71. Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg 2007; 84: 324-338 [PMID: 17588454]
72. Kim HK, Cho JH, Lee HY, Lee J, Kim J. Pulmonary metastasectomy for colorectal cancer: how many nodules, how many times? World J Gastroenterol 2014; 20: 6133-6145 [PMID: 24876735 DOI: 10.3748/wjg.v20.i20.6133]
73. Hishida T, Okumura T, Boku N, Y O. Surgical outcome for pulmonary metastasis of colorectal cancer in the modern chemotherapy era: Results of a retrospective Japanese multicenter study. J Clin Oncol 2014; 32 (suppl): abstr 3528
74. Shiono S, Ishii G, Nagai K, Yoshida J, Nishimura M, Murata Y, Tsuta K, Nishiwaki Y, Kodama T, Ochiai A. Histopathologic prognostic factors in resected colorectal lung metastases. Ann Thorac Surg 2005; 79: 278-282; discussion 283 [PMID: 15620957]
75. Vogelsang H, Haas S, Hierholzer C, Berger U, Siewert JR, Präuer H. Factors influencing survival after resection of pulmonary metastases from colorectal cancer. Br J Surg 2004; 91: 1066-1071 [PMID: 15286972]
76. Watanabe I, Arai T, Ono M, Sugito M, Kawashima K, Ito M, Nagai K, Saito N. Prognostic factors in resection of pulmonary metastasis from colorectal cancer. Br J Surg 2003; 90: 1436-1440 [PMID: 14598428]
77. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian GastroIntestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016 [PMID: 18358928 DOI: 10.1016/S0140-6736(08)60455-9]
78. Adam R, Barroso E, Laurent C, Nuzzo G, Hubert C, Mentha G, Ijzermans J, Capussotti L, Lopezben S, Mirza D, Kaiser G, Oussoultzoglou E, Gruenberger T, Poston GJ, Skipenko O. The LiverMetSurvey Centers. Impact of the type and modalities of the type and modalties of preoperative chemotherapy on the outcome of liver resection for colorectal metastases. J Clin Oncol 2011; 29: (abstr 3519)
79. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-2072 [PMID: 16648507]
80. Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007; 11: 860-868 [PMID: 17492335]
81. Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber JC, Bachellier P. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg 2004; 240: 1037-1049; discussion 1049-1051 [PMID: 15570209]
82. Adam R, Miller R, Pitombo M, Wicherts DA, de Haas RJ, Bitsakou G, Aloia T. Two-stage hepatectomy approach for initially unresectable colorectal hepatic metastases. Surg Oncol Clin N Am 2007; 16: 525-536, viii [PMID: 17606192]
83. Schnitzbauer AA, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA, Fichtner-Feigl S, Lorf T, Goralcyk A, Hörbelt R, Kroemer A, Loss M, Rümmele P, Scherer MN, Padberg W, Königsrainer A, Lang H, Obed A, Schlitt HJ. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 2012; 255: 405-414 [PMID: 22330038 DOI: 10.1097/SLA.0b013e31824856f5]
84. Ratti F, Schadde E, Masetti M, Massani M, Zanello M, Serenari M, Cipriani F, Bonariol L, Bassi N, Aldrighetti L, Jovine E. Strategies to Increase the Resectability of Patients with Colorectal Liver Metastases: A Multi-center Case-Match Analysis of ALPPS and Conventional Two-Stage Hepatectomy. Ann Surg Oncol 2015; 22: 1933-1942 [PMID: 25564160 DOI: 10.1245/s10434-014-4291-4]
85. Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 2007; 246: 559-565; discussion 565-567 [PMID: 17893492]
86. Gleisner AL, Choti MA, Assumpcao L, Nathan H, Schulick RD, Pawlik TM. Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg 2008; 143: 1204-1212 [PMID: 19075173 DOI: 10.1001/archsurg.143.12.1204]
87. Pawlik TM, Izzo F, Cohen DS, Morris JS, Curley SA. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol 2003; 10: 1059-1069 [PMID: 14597445]
88. Eltawil KM, Boame N, Mimeault R, Shabana W, Balaa FK, Jonker DJ, Asmis TR, Martel G. Patterns of recurrence following selective intraoperative radiofrequency ablation as an adjunct to hepatic resection for colorectal liver metastases. J Surg Oncol 2014; 110: 734-738 [PMID: 24965163 DOI: 10.1002/jso.23689]
89. Cirocchi R, Trastulli S, Boselli C, Montedori A, Cavaliere D, Parisi A, Noya G, Abraha I. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Database Syst Rev 2012; 6: CD006317 [PMID: 22696357 DOI: 10.1002/14651858.CD006317.pub3]
90. Kingham TP, Tanoue M, Eaton A, Rocha FG, Do R, Allen P, De Matteo RP, D'Angelica M, Fong Y, Jarnagin WR. Patterns of recurrence after ablation of colorectal cancer liver metastases. Ann Surg Oncol 2012; 19: 834-841 [PMID: 21879262 DOI: 10.1245/s10434-011-2048-x]
91. Langer B, Bleiberg H, Labianca R, Shepherd L, Nitti D, Marsoni S, Tu D, Sargeant AM, Fields A. Fluorouracil (FU) plus leucovorin (I-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC/CTG/GIVIO) randomized trial. Proc Am Clin Oncol 2002; 21: abstract 592
92. Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, Belghiti J, Piedbois P, Guimbaud R, Nordlinger B, Bugat R, Lazorthes F, Bedenne L. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24: 4976-4982 [PMID: 17075115]
93. Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V, Elias D, O'Callaghan C, Langer B, Martignoni G, Bouché O, Lazorthes F, Van Cutsem E, Bedenne L, Moore MJ, Rougier P. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008; 26: 4906-4911 [PMID: 18794541 DOI: 10.1200/JCO.2008.17.3781]
94. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14: 1208-1215 [PMID: 24120480 DOI: 10.1016/S1470-2045(13)70447-9]
95. Kanemitsu Y, Kato T, Shimizu Y, Inaba Y, Shimada Y, Nakamura K, Sato A, Moriya Y; Colorectal Cancer Study Group (CCSG) of Japan Clinical Oncology Group. A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603. Jpn J Clin Oncol 2009; 39: 406-409 [PMID: 19389795 DOI: 10.1093/jjco/hyp035]
96. Nakayama I, Suenaga M, Wakatsuki T, Ichimura T, Ozaka M, Takahari D, Shinozaki E, Chin K, Ueno M, Mizunuma N, Yamaguchi T. Safety, tolerability, and efficacy of oxaliplatin-based adjuvant chemotherapy after curative resection of hepatic or extrahepatic metastases of Stage IV colorectal cancer. Cancer Chemother Pharmacol 2015; 76: 133-139 [PMID: 25994854 DOI: 10.1007/s00280-015-2780-1]
97. Katayose Y, Yamamoto K, Nakagawal K, Takemura S, Takahashi M, Nakamura R, Shimamura H, Rikiyama T, Egawa S, Yoshda H, Motoi F, Naitoh T, Unno M. Feasibility Assessment of Modifed FOLFOX-6 as adjuvant treatment after resection of liver metastases from colorectal cancer: analyses of a multicenter phase II clinical trial (Miyagi-HBPCOG Trial-001). Hepatogastroenterology 2015; 62: 303-308 [PMID: 25916054]
98. Kim HR, Min BS, Kim JS, Shin SJ, Ahn JB, Rho JK, Kim NK, Rha SY. Effcacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis. Oncology 2011; 81: 175-183 [PMID: 22057187 DOI: 10.1159/000333440]
99. Kim SY, Kim HJ, Hong YS, Jung KH, Park JW, Choi HS, Oh JH, Park SJ, Kim SH, Nam BH, Chang HJ, Kim DY. Resected colorectal liver metastases: does the survival differ according to postoperative chemotherapy regimen? J Surg Oncol 2009; 100: 713-718 [PMID: 19771561 DOI: 10.1002/jso.21403]
100. Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, Shacham-Shmueli E, Rivera F, Kwok-Keung Choi C, Santoro A. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 2009; 20: 1964-1970 [PMID: 19567451 DOI: 10.1093/annonc/mdp236]
101. Liu JH, Hsieh YY, Chen WS, Hsu YN, Chau GY, Teng HW, King KL, Lin TC, Tzeng CH, Lin JK. Adjuvant oxaliplatin-or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases. Int J Colorectal Dis 2010; 25: 1243-1249 [PMID: 20574727 DOI: 10.1007/s00384-010-0996-4]
102. Brandi G, Derenzini E, Falcone A, Masi G, Loupakis F, Pietrabissa A, Pinna AD, Ercolani G, Pantaleo MA, Di Girolamo S, Grazi GL, de Rosa F, Biasco G. Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. Clin Colorectal Cancer 2013; 12: 188-194 [PMID: 23773458 DOI: 10.1016/j.clcc.2013.04.002]
103. Kobayashi A, Hasegawa K, Saiura A, Takayama T, Miyagawa S, Yamamoto J, Bandai Y, Teruya M, Yoshimi F, Kawasaki S, Koyama H, Oba M, Takahashi M, Mizunuma N, Matsuyama Y, Watanabe T, Makuuchi M, Kokudo N. A randomized controlled trial evaluating efficacy of adjuvant oral uracil-tegafur (UFT) with leucovorin (LV) after resection of colorectal cancer liver metastases; the UFT/LV study. J Clin Oncol 2014; 32: 5 suppl (abstr 3584)
104. Kato T, Uehara K, Maeda A, Sakamoto E, Hiramatsu K, Takeuchi E, Goto H, Tojima Y, Yatsuya H, Nagino M; Nagoya Surgical Oncology Group. Phase II multicenter study of adjuvant S-1 for colorectal liver metastasis: survival analysis of N-SOG 01 trial. Cancer Chemother Pharmacol 2015; 75: 1281-1288 [PMID: 25929347 DOI: 10.1007/s00280-015-2752-5]
105. Kemeny NE, Jarnagin WR, Capanu M, Fong Y, Gewirtz AN, Dematteo R P, D'Angelica MI. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol 2011; 29: 884-889 [PMID: 21189384 DOI: 10.1200/JCO.2010.32.5977]
106. Turan N, Benekli M, Koca D, Ustaalioglu BO, Dane F, Ozdemir N, Ulas A, Oztop I, Gumus M, Ozturk MA, Berk V, Kucukoner M, Uner A, Balakan O, Helvaci K, Ozkan S, Yilmaz U, Buyukberber S. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer. Oncology 2013; 84: 14-21 [PMID: 23076023 DOI: 10.1159/000342429]
107. Snoeren N, Voest EE, Bergman AM, Dalesio O, Verheul HM, Tollenaar RA, van der Sijp JR, Schouten SB, Rinkes IH, van Hillegersberg R. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. BMC Cancer 2010; 10: 545 [PMID: 20937118 DOI: 10.1186/1471-2407-10-545]
108. Primrose J, Falk S, Finch-Jones M, Valle J, O'Reilly D, Siriwardena A, Hornbuckle J, Peterson M, Rees M, Iveson T, Hickish T, Butler R, Stanton L, Dixon E, Little L, Bowers M, Pugh S, Garden OJ, Cunningham D, Maughan T, Bridgewater J. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 2014; 15: 601-611 [PMID: 24717919 DOI: 10.1016/S1470-2045(14)70105-6]
109. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560 [PMID: 12958120]
110. Xing M, Kooby DA, El-Rayes BF, Kokabi N, Camacho JC, Kim HS. Locoregional therapies for metastatic colorectal carcinoma to the liver-an evidence-based review. J Surg Oncol 2014; 110: 182-196 [PMID: 24760444]
111. Kingham TP, D'Angelica M, Kemeny NE. Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases. J Surg Oncol 2010; 102: 988-995 [PMID: 21166003 DOI: 10.1002/jso.21753]
112. Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, Bertino JR, Turnbull AD, Sullivan D, Stockman J, Blumgart LH, Fong Y. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341: 2039-2048 [PMID: 10615075]
113. Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med 2005; 352: 734-735 [PMID: 15716576]
114. House MG, Kemeny NE, Gönen M, Fong Y, Allen PJ, Paty PB, DeMatteo RP, Blumgart LH, Jarnagin WR, D'Angelica MI. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg 2011; 254: 851-856 [PMID: 21975318 DOI: 10.1097/SLA.0b013e31822f4f88]
115. Alberts SR, Roh MS, Mahoney MR, O'Connell MJ, Nagorney DM, Wagman L, Smyrk TC, Weiland TL, Lai LL, Schwarz RE, Molina R, Dentchev T, Bolton JS. Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66. J Clin Oncol 2010; 28: 853-858 [PMID: 20048179 DOI: 10.1200/JCO.2009.24.6728]
116. Ota M, Masui H, Tanaka K, Ichikawa Y, Yamaguchi S, Togo S, Ike H, Oki S, Shimada H. [Efficacy of adjuvant hepatic arterial infusion chemotherapy following resection of colorectal liver metastases]. Gan To Kagaku Ryoho 1999; 26: 1698-1701 [PMID: 10560374]
117. Goéré D, Benhaim L, Bonnet S, Malka D, Faron M, Elias D, Lefèvre JH, Deschamps F, Dromain C, Boige V, Dumont F, De Baere T, Ducreux M. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. Ann Surg 2013; 257: 114-120 [PMID: 23235397 DOI: 10.1097/SLA.0b013e31827b9005]